KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Major Shareholder Purchases $134,261.64 in Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) major shareholder Venrock Healthcare Capital Par acquired 14,562 shares of the stock in a transaction dated Monday, February 3rd. The shares were bought at an average price of $9.22 per share, for a total transaction of $134,261.64. Following the transaction, the insider now owns 5,012,796 shares in the company, valued at approximately $46,217,979.12. This represents a 0.29 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Thursday, January 30th, Venrock Healthcare Capital Par acquired 43,707 shares of KalVista Pharmaceuticals stock. The stock was acquired at an average price of $8.76 per share, for a total transaction of $382,873.32.

KalVista Pharmaceuticals Stock Performance

NASDAQ:KALV traded up $0.31 during midday trading on Monday, reaching $9.22. 362,712 shares of the stock traded hands, compared to its average volume of 290,024. KalVista Pharmaceuticals, Inc. has a 12-month low of $7.30 and a 12-month high of $16.88. The business has a 50-day moving average of $8.81 and a two-hundred day moving average of $10.81. The stock has a market capitalization of $455.65 million, a PE ratio of -2.53 and a beta of 0.85.

KalVista Pharmaceuticals (NASDAQ:KALV) last released its earnings results on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) EPS for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.01. Research analysts anticipate that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current year.

Institutional Trading of KalVista Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in KALV. Vestal Point Capital LP raised its holdings in shares of KalVista Pharmaceuticals by 73.9% during the third quarter. Vestal Point Capital LP now owns 4,000,000 shares of the specialty pharmaceutical company’s stock valued at $46,320,000 after acquiring an additional 1,700,000 shares during the last quarter. State Street Corp grew its holdings in shares of KalVista Pharmaceuticals by 68.1% in the third quarter. State Street Corp now owns 1,271,609 shares of the specialty pharmaceutical company’s stock valued at $14,725,000 after purchasing an additional 515,179 shares during the period. Emerald Advisers LLC increased its holdings in shares of KalVista Pharmaceuticals by 29.8% during the 3rd quarter. Emerald Advisers LLC now owns 835,988 shares of the specialty pharmaceutical company’s stock worth $9,681,000 after buying an additional 192,091 shares during the last quarter. Readystate Asset Management LP purchased a new stake in KalVista Pharmaceuticals in the third quarter valued at $2,084,000. Finally, Emerald Mutual Fund Advisers Trust lifted its position in KalVista Pharmaceuticals by 23.0% in the third quarter. Emerald Mutual Fund Advisers Trust now owns 650,980 shares of the specialty pharmaceutical company’s stock valued at $7,538,000 after buying an additional 121,615 shares during the last quarter.

Analyst Upgrades and Downgrades

KALV has been the subject of several analyst reports. Needham & Company LLC restated a “buy” rating and set a $28.00 price target on shares of KalVista Pharmaceuticals in a report on Thursday, December 5th. Bank of America assumed coverage on KalVista Pharmaceuticals in a research note on Wednesday, December 18th. They set a “buy” rating and a $22.00 price target for the company. JMP Securities initiated coverage on KalVista Pharmaceuticals in a research report on Friday. They set an “outperform” rating and a $19.00 target price on the stock. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of KalVista Pharmaceuticals in a research report on Friday, December 6th. Finally, Citizens Jmp upgraded KalVista Pharmaceuticals to a “strong-buy” rating in a research note on Friday. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $23.80.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).